0001193125-24-072709.txt : 20240320 0001193125-24-072709.hdr.sgml : 20240320 20240320161304 ACCESSION NUMBER: 0001193125-24-072709 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240320 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc. CENTRAL INDEX KEY: 0001501756 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 205258327 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36579 FILM NUMBER: 24767932 BUSINESS ADDRESS: STREET 1: 100 CARDINAL WAY CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: (650) 649-1004 MAIL ADDRESS: STREET 1: 100 CARDINAL WAY CITY: REDWOOD CITY STATE: CA ZIP: 94063 FORMER COMPANY: FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc. DATE OF NAME CHANGE: 20100921 8-K 1 d814195d8k.htm 8-K 8-K
NASDAQ false 0001501756 --12-31 0001501756 2024-03-20 2024-03-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

March 20, 2024

Date of Report (Date of earliest event reported)

 

 

Adverum Biotechnologies, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-36579   20-5258327
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification Number)

100 Cardinal Way

Redwood City, CA 94063

(Address of principal executive offices, including zip code)

(650) 656-9323

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title Of Each Class

  

Trading
Symbol

  

Name Of Each Exchange

On Which Registered

Common Stock   ADVM   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.03

Material Modification to Rights of Security Holders.

The information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

As previously disclosed in a Current Report on Form 8-K filed by Adverum Biotechnologies, Inc. (the “Company”) with the Securities and Exchange Commission on June 9, 2023, the Company held its annual meeting of stockholders on June 9, 2023, at which meeting the Company’s stockholders approved a reverse stock split at a ratio of 1-for-5, 1-for-7, 1-for-10, 1-for-12 or 1-for-20 (such ratio to be determined in the sole discretion of the Company’s Board of Directors) and the filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company to effectuate such reverse stock split, which approval is valid through June 9, 2024.

On March 8, 2024, the Company’s Board of Directors determined to effectuate the reverse stock split of the common stock at a 1-for-10 ratio (the “Reverse Stock Split”) and approved the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Amended and Restated Certificate of Incorporation of the Company to effect the Reverse Stock Split. On March 20, 2024, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split effective as of 12:01 a.m. Eastern time on March 21, 2024 (the “Effective Time”). At the Effective Time, every 10 shares of issued and outstanding common stock will be automatically combined into one issued share of common stock, without any change in the par value per share. The total number of authorized shares of common stock will remain at 300,000,000, notwithstanding the Reverse Stock Split. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders otherwise entitled to receive a fractional share as a result of the Reverse Stock Split will receive a cash payment in lieu of such fractional share.

Additionally, on March 20, 2024, the Company filed a Restated Certificate of Incorporation of the Company (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which restates and integrates but does not further amend the Company’s Certificate of Incorporation, as then amended. The Restated Certificate will become effective at 12:02 a.m. Eastern time on March 21, 2024.

Copies of the Certificate of Amendment and Restated Certificate are filed as Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

 3.1    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Adverum Biotechnologies, Inc., effecting Reverse Stock Split at 12:01 a.m. Eastern time on March 21, 2024.
 3.2    Restated Certificate of Incorporation of Adverum Biotechnologies, Inc., to be effective at 12:02 a.m. Eastern time on March 21, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    Adverum Biotechnologies, Inc.
Dated: March 20, 2024     By:  

/s/ Laurent Fischer

     

Laurent Fischer, M.D.

President and Chief Executive Officer

 EX-3.1 2 d814195dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT OF THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF ADVERUM BIOTECHNOLOGIES, INC.

Adverum Biotechnologies, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that:

FIRST: The name of this corporation is Adverum Biotechnologies, Inc. (the “Company”).

SECOND: The date of filing of the original Certificate of Incorporation of this Company with the Secretary of State of the State of Delaware was July 17, 2006 under the name “Avalanche Biotechnologies, Inc.,” a certificate of correction was filed with the Secretary of State of the State of Delaware on August 11, 2010, an amended and restated certificate of incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on August 27, 2010, amendments to the amended and restated certificate of incorporation of the Corporation were filed with the Secretary of State of the State of Delaware on March 5, 2013 and November 8, 2013, amended and restated certificates of incorporation of the Corporation were filed with the Secretary of State of the State of Delaware on April 15, 2014 and August 5, 2014 and an amendment to the amended and restated certificate of incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on May 11, 2016 (as amended, the “Certificate of Incorporation”).

THIRD: Paragraph A of ARTICLE IV of the Corporation’s Amended and Restated Certificate of Incorporation be, and it hereby is, amended and restated to read in its entirety as follows:

“A. This Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares that the Corporation is authorized to issue is Three Hundred Five Million (305,000,000) shares, divided into Three Hundred Million (300,000,000) shares of Common Stock and 5,000,000 shares of Preferred Stock. The Common Stock shall have a par value of $0.0001 per share and the Preferred Stock shall have a par value of $0.0001 per share. Effective as of 12:01 a.m. Eastern time, on the date immediately following the date this Certificate of Amendment of Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware, each 10 shares of the Corporation’s Common Stock issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one share of Common Stock; provided, however, that the Corporation shall issue no fractional shares as a result of the actions set forth herein but shall instead pay to the holder of such fractional share a sum in cash equal to such fraction multiplied by the closing sales price of the Corporation’s Common Stock as reported on the Nasdaq Global Market (or such other principal market upon which its Common Stock is traded) on the last business day before the date this Certificate of Amendment of Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware, such amount rounded to the nearest whole cent.”

FOURTH: The foregoing amendment was submitted to the stockholders of the Corporation for their approval, and was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

****

IN WITNESS WHEREOF, Adverum Biotechnologies, Inc. has caused this Certificate of Amendment to be signed by its Chief Executive Officer this 20th day of March, 2024.

 

ADVERUM BIOTECHNOLOGIES, INC.
By:  

/s/ Laurent Fischer

Name:   Laurent Fischer, M.D.
Title:   Chief Executive Officer
 EX-3.2 3 d814195dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

RESTATED

CERTIFICATE OF INCORPORATION

OF

ADVERUM BIOTECHNOLOGIES, INC.

Adverum Biotechnologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), hereby certifies as follows:

FIRST: The name of this corporation is Adverum Biotechnologies, Inc.

SECOND: The original certificate of incorporation of this corporation was filed with the Secretary of State of the State of Delaware on July 17, 2006 under the name “Avalanche Biotechnologies, Inc.”

THIRD: This Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of Section 245 of the Delaware General Corporation Law. This Restated Certificate of Incorporation only restates and integrates and does not further amend the provisions of this corporation’s amended and restated certificate of incorporation, as heretofore amended or supplemented, and there is no discrepancy between those provisions and the provisions of this Restated Certificate of Incorporation.

FOURTH: The certificate of incorporation of this corporation is hereby restated in its entirety as follows:

ARTICLE I

The name of the corporation is Adverum Biotechnologies, Inc. (the “Corporation”).

ARTICLE II

The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, DE 19808, County of New Castle. The name of its registered agent at such address is Corporation Service Company.

ARTICLE III

The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law.

ARTICLE IV

A. This Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares that the Corporation is authorized to issue is Three Hundred Five Million (305,000,000) shares, divided into Three Hundred Million (300,000,000) shares of Common Stock and 5,000,000 shares of Preferred Stock. The Common Stock shall have a par value of $0.0001 per share and the Preferred Stock shall have a par value of $0.0001 per share.

 

1

B. The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Corporation (the “Board of Directors”) is hereby authorized, by filing a certificate (a “Certificate of Designation”) pursuant to the Delaware General Corporation Law, to fix or alter from time to time the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions of any wholly unissued series of Preferred Stock, and to establish from time to time the number of shares constituting any such series or any of them; and to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.

ARTICLE V

For the management of the business and for the conduct of the affairs of the Corporation, and in further definition, limitation and regulation of the powers of the Corporation, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that:

A. (1) The management of the business and the conduct of the affairs of the Corporation shall be vested in the Board of Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed exclusively by one or more resolutions adopted from time to time by the Board of Directors.

(2) The directors shall be divided into three classes, designated as Class I, Class II and Class III, as nearly equal in number as possible. Directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following the effectiveness of this Amended and Restated Certificate of Incorporation (the “Qualifying Record Date”), the term of office of the Class I directors shall expire and Class I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following the Qualifying Record Date, the term of office of the Class II directors shall expire and Class II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following the Qualifying Record Date, the term of office of the Class III directors shall expire and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting.

Notwithstanding the foregoing provisions of this Article V(A), each director shall serve until his or her successor is duly elected and qualified or until his or her death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

(3) The Board of Directors or any individual director may be removed from office at any time (i) with cause by the affirmative vote of the holders of a majority of the voting power of all the then outstanding shares of voting stock of the Corporation entitled to vote at an election of directors (the “Voting Stock”) or (ii) without cause by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of Voting Stock.

(4) Any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified.

 

2

B. (1) Subject to Article X of the Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, alter or repeal Bylaws of the Corporation. Notwithstanding the foregoing, the Bylaws of the Corporation may be rescinded, altered, amended or repealed in any respect by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all the then-outstanding shares of the Voting Stock.

(2) The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.

ARTICLE VI

A. Subject to the rights of the holders of any series of Preferred Stock or any other class of stock or series thereof having a preference over the Common Stock as to dividends or upon liquidation, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of the stockholders of the Corporation, and the taking of any action by written consent of the stockholders in lieu of a meeting of the stockholders is specifically denied.

B. Special meetings of the stockholders of the Corporation may be called, for any purpose or purposes, by the Secretary of the Corporation at the direction of the Board of Directors, pursuant to a resolution adopted by a majority of the entire Board of Directors, but such special meetings may not be called by any other person or persons.

C. Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.

ARTICLE VII

A. To the maximum extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article VII to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law as so amended.

B. The Corporation may indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she, or his or her testator or intestate is or was a director, officer, employee or agent of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as a director, officer, employee or agent at the request of the Corporation or any predecessor to the Corporation.

C. Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of the Corporation’s certificate of incorporation inconsistent with this Article VII, shall eliminate or reduce the effect of this Article VII in respect of any matter occurring, or any action or proceeding accruing or arising or that, but for this Article VII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.

 

3

ARTICLE VIII

Unless the Corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or (iv) any action asserting a claim governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants.

ARTICLE IX

Notwithstanding any other provisions of this Amended and Restated Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Voting Stock required by law, this Amended and Restated Certificate of Incorporation or any Certificate of Designation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the Voting Stock, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII, VIII and IX.

FIFTH: This Restated Certificate of Incorporation shall be effective as of 12:02 a.m. Eastern time on March 21, 2024.

****

 

4

IN WITNESS WHEREOF, Adverum Biotechnologies, Inc. has caused this Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 20th day of March, 2024.

 

ADVERUM BIOTECHNOLOGIES, INC.
By:  

/s/ Laurent Fischer

Name:   Laurent Fischer, M.D.
Title:   Chief Executive Officer

 

5

EX-101.SCH 4 advm-20240320.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 advm-20240320_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 advm-20240320_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information
Mar. 20, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001501756
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Mar. 20, 2024
Entity Registrant Name Adverum Biotechnologies, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36579
Entity Tax Identification Number 20-5258327
Entity Address, Address Line One 100 Cardinal Way
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94063
City Area Code (650)
Local Phone Number 656-9323
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ADVM
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *"!=%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "@@718/2T'*.T K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VW%0^CFLN))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA>1Z%#PN<4(B:RF&\F-_@L=-RP(U$4 %D?T:E)J&'JZ &4:87/XNH%F)2_5/[-(!=DY.V:ZI<1SKL5MR98<&WIX>7Y9U*^LS M*:^Q_,I6T"GBAETFOW;;^]T#DRUO;RO>52W?M5PTG>#\?7;]X7<5=L'8O?W' MQA=!V<.ONY!?4$L#!!0 ( *"!=%B97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MH(%T6,=JU:9=! &!$ !@ !X;"]W;W)K+A6TW$HEX@D3FDM!%-M,G)E_9+[7UGY0CE@*&.=_R?[HF_/1!%MF+6Q:^ AMJL;EH*WA6!P M1O"1JBL2>!_@+^C]=[@+;!5@4 $&N5[WC-YL;G=*031Q(7,W4&W.F/_[@#[Q?$+YNQ=?%U*A7''U4ITRF.9 H M&D-21>Q /K%C$Q&NY'F>W_?\87^ 8 TJK $J-L^4RB>'ZQ"P_F!40=Y'!%9/ M8]1PM4['#SI='^$:5EQ#5*E:B,_'M!$$'W[=^81 7%<0UY=!+)GB,D(G!E>J M;*#-!T85VNB2='IB6VZ= !C/K3-<9Q:!GV0)N>72L' G9"RWG.D/D*#A%<+I M>[6C>I>0@IY4J52YCY*5@6DD&+Y_B6 ]SP&L\J2 M-5.-++@(K,E.=] ?CC"DVN1]U*/?D9[I@3Q$D(!\P\-BXA! 7#+P.OV@?]T- MAAAA;?,^[L\EX2R*8 ^!="DOR&?H1[Z*YG#BDK[GD3E5$1=@1"_TB''6[N_C M]OT]Y]RVI"+/H_P<6O_+.W&N=Q)@=H'+C+H#SJC;H!.3KTU^+BGOT !9IB J4F2 M3)3.H1NI<*&VVB>H-X$ M^J5C'G(#1=;\@@)KCB-&RM77*65I_;\ +?KI6+Y M]#!88469 54B%-9?-YOF^+7HM9*=U/>X3_^/[$'K#,A: 7'95L#:^8,+*WP_ M6)-G;N+&Y=WH MP46.?I&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M; M<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQ MMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!I MK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+; M.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B M<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI; M"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R M%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,3 M1S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z? M^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WB MDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7X MC&894IT,/O'^8* \^>Q\ETWLJ.?]7 M4_P$4$L#!!0 ( *"!=%B7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - d814195d8k.htm 7 advm-20240320.xsd advm-20240320_lab.xml advm-20240320_pre.xml d814195d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d814195d8k.htm": { "nsprefix": "advm", "nsuri": "http://www.adverum.com/20240320", "dts": { "schema": { "local": [ "advm-20240320.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "advm-20240320_lab.xml" ] }, "presentationLink": { "local": [ "advm-20240320_pre.xml" ] }, "inline": { "local": [ "d814195d8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-20_to_2024-03-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d814195d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-20_to_2024-03-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d814195d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.adverum.com//20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-24-072709-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-072709-xbrl.zip M4$L#!!0 ( *"!=%BMHAW /@, $H+ 1 861V;2TR,#(T,#,R,"YX M;-';@I;&#E&*5$DJ MB?]]AY3DR$[L.DE17TQSYLV\^:1//C[4$N[06*'5-,J2- )4I:Z$6DZCUL;< MED)$'T_?OSOY+H[A_.+R&F*X=:ZQ!6/W]_=)M1#*:MDZLF"34M<,XGC0__7F M*_S162]@AA*Y1:BY=6C@EU;(JLC3?)*E69[D8YA![NU!Q1T6,&%YQDCQ)\CR M(OU0'/T,9Y_A4S"CX$;4.,;J9F7$\M;!]^4/$%#G6BF4$E=P(117I> 2O@R4 M?X1+529P)B7,/,P23XOF#JNDM_I@J\*6MUCS]^\ *&'*%HI,MO4T\IGH$_$P M-S+19LDJ9YA;-K M+Z'3HE,/ C-)^I&&P==#U[I,LS&GFSZ7_%0A-A?Q5D>3[*$C$6@GB6]HX+ MWDQDJ.VKB*P;XV B=E<#^T/L#[N\/]_VK\[ ]CC[^(]]_-F'@^)_L@[^ R9: M7;^5S&BGO;XFBHNR6UG=\?"Z/"+?U)O#4O!Y.-KK>'N+]%Z#3ZZ4=L'1F EO M&J$6NK^B2]_$Q=#),UQ V%X%-Z71$O?O.-88W:!Q@E;\XS!T!FX-+J:1W_3Q ML&>^23Y/:,\,*D\<;(Z7%S."H+QZI#=@G7 >?.7%X.7T5G*Y-NW;81I9RKL< MC>?_'&YC\*7A$L32<@]EVQWU[R.M%P?O_=R0!OC#U]GESN=A_3XPQQ^TTO6J MXWBNR]:_0,/WF:H^*6*VNJ3&,G5@%8&@AV1&ZM\.4E]S'%A62'_=1.C>+/4? M^FR=LV\BV_=9B]9LZ#>>2R[*5ZYSWX%YC'W"[6H]N^K6#?W\!U!+ P04 " "@@718LU]PM94& "L M1@ %0 &%D=FTM,C R-# S,C!?;&%B+GAM;,V<;6_;-A#'WQ?H=[AY;S:@ MLF-G#ZC1M,B6PKQYMXX8W!.IJ. GO6'_J >$!R*D?'[26RG/5P&E/5"QST.?"4Y. M>ANB>N_>OGSQYAO/@[.+RX_@P2*.EVH\&#P\//3#.\J58*M82ZI^(*(!>%X> M/YE^AM_2DJPSP3EAC&S@ M@G*?!]1G<)NW_ HN>="'4\;@DTE3ND]%Y#T)^YDJH_S?L?EK9KJ'ER\ ],O( M57+NI&=>C.RU6,\DZPLYU\T>'0_RE-YCQGHGY>$X21B^?OUZD%PM1BMJB]7B MP\$?'ZYN@P6)?$^__/K+%61E%!VKY/R5")+7L$:#4!IA_N?E89XYY0U'WO&P MOU9A[ZTIF+TZ_HRP*WT$B8>Q%(Q4%#:7D^J]+#[>+'4\6<>$AR13_JHM@BQJ M(8F$ MS$\F)DYZEJ3!=D,F[E0&6UJ^#'(=?;C'?Q8Q"(3^NBUC+U',T^^DB*Q=9.6$ MY>(7-F/6-@U)^LB,-^'>Y]M]7E.AHC%)E%A)C5>3+VWBYVVB#'_GVO^\&3S6 M?BZMZK<01:Z:]NN&Y"T)5I+&F_-UL-!^R4<_(G7)M.=V!&BE$5$>XX)KN1X2 MM7D!R"N *>',;GM]%Q%NVKP;R*>1?K_6?^(+YL_K$OPDJ2-T[:T+RT476"U" M2)1^508C[4QG"XT6L:S;K1N.YSS6Z$]T&>FS2[V26/]*-G6Q+$GN",]J*Z(B MR 77"D$D;-,*D)6 I ;H(LX M]AZ$>3F_3NN7E=2FJFD*O#9G\27YSP\TQ^* M:B]D2_.[6M/N,R2JXYQ6NI6:6(O>M BD5<"4 5T'3"'W!7"K#K;6P@?9<(/] M3 0K\TUBJAW4!7P[IR.HK8V+W6LN\.[J( &;"X-1=B84O\TBE35[Q<'PAD@J MPH9ON"7)'8-IMR(J@C!0M0AB,YN6P'N#;;%U*\>U^\=8&7\BVZGZ^(2(Z(\QGU5;-/#710_5L"YX]!>WY85<>WF,4"^Y(&02R&3&]RWL1Z< MB5CI%?EF(L*&7.^1ZA3S>C9%[13W(:@ACSL36P4AJ0A923 UD8;D?_!EF9G# MS6$,T05EY.,JFA'9;&**>9V.A\6 L%]W!_^I%B[E1AU2>22@L?NUT%NK:0Q0 MI_[Z,M2+)7I'TT>:AU!;*M(IPONLB1K![G!7"N.2KDO!=BU<[ENU8AF" _Q@ MC,1I&&H#*OOGBG(R;#8.5H%.1Z'*DM@3Z#X"I:*X^&?ZK_(#,)7@FF.M8UJS M84'_ "^(Z$_TX;6 O<6.#?K',#3DGTJV!+PI T*"*80+.[:! M*M3KN4#$//E0<"UOI+BG/&CXV;9,XSD 7V;,1OV36#3TK;HM\9]^NM/HY-5P MAZ 5*U63T, /XCC<"!7[["^Z;'ZCQZ[P'$;!;LHV"%N1:&-@46UI"-)*H$MA MWKQIST;5 -3VXO@# ,:@)'X3X+=SNGK0;VM<[%YS>J"_HX,$;O)]WBCC<(K? MY]:C^IK-NH%H?IZO(R!+#0C[=1.LR4*P#:2%(*CF#WK:)(O '.D%%_U*I%9'N V#1>1YC4&[0/@P[\8@C M4:+=UF"DY5J=CY8<54Y)(ULX>R&'H]F4QJSQ/LC'O([W0.X8$/;K&'L?M[6P M%C7YUD&M#HD\VIY'W'ZM^QUK-.T&ZE3ZYM_C2YPUW/)9(=/I@ MI-J6V!OJ_FBD0A;WV4A>"-)*D)5">C32H@W+LY&Z7HHGKO21^24KV2F:_JH1 M?>8_4$L#!!0 ( *"!=%A_GPK(U@0 #LL 5 861V;2TR,#(T,#,R M,%]P&ULU9I=C^(V%(;O5]K_X*8WK=00 C.['33,BC+,"I7Y$+#]NEF9 MY !6'3NRG0'^?>V 6P+)+$RW5(Y89+33.F0LA'Q)$"^;^OWIY_0+]OF.F@,%+ $E&"I0*"?,D+C3JO9 M:H?-L-5H[2<O61^)5NU< M$EY=707YT6)]2; (C"6YYE"7 E/WLL7C %%&;(9MSD>0=\5"> MT\Y2P+SKZ:B);Z,9.]^.=:#/YP12FU2?%Y(D*04/!7O=284>.DSEM4>ZH"" MM0(60VS#F [\-QV^V3+=#5P>%1)@S]T#/00S$M-@V7TQVVGEF](_/ M?:Y-]692"1RI8@:H&2EEJ=JUQE_RRT4, MHNNU6@T]!7@H%82;2KK$0YG4EGAJS&-JCL$0UOS*S MGAZJL1FN=Q0O3H5U(*HOI0.C%D_;&3S;&:2O>R P'>HY:OTS;$[%5"&N+ZX* MPQ;;A3/8^IDP2;@C,L+T=\!BP.);?<-T\BQ=J:\OO&K/EM^E,_SL-7RJ,WDJ MLZ*FOIR*/BV;]\ZQ>0+M-3[SQ*H0UY_6@6&+[4=GL&WG]C$LB.DH4^?<')9K MZPNMW*]E=N48,_T0SD7*19[:B ZTR2-T)5AJW.-UY MZ-YVJ!?'.LER]S$B#,+S4)8&J#O&4M,6H6L/YKM>]/771S'E*_8J@/MR1_#M M6[;PW'D\+W0EOXX_BB?!GXE9I7\-P:,8CF \\FU9NO.H7NC/$Y<*TS](>OZM M:7D$1S@>N+84WSE#TG3DK,S'Q*.=?5E M=.S557[4\!Z_,DR=CN'EF>"JM"7%]B%88M-G<662:B^Y MMA3=64\YZ,U0R@S$OV=9$L<9HB7>+5=W%E;LKHRP-9L21<_>??*/KK[ MDXH0]47WHFT+\G]8'+D.CE(ST@5FS^OVB'DS.SAUR5]02P,$% @ H(%T M6.F?&--L$0 7&P X !D.#$T,3DU9#AK+FAT;>U=47/B.!)^SZ]0,;6[ M254,MH$DD Q7#&%VV9TDPN$]]%E>G]F.6'WC 1#@J6MX(6:_H95-/ MV/#Y*B: L%'Z\^93SQJR$=6XZP?4M9(NPD#D,E0K06EQ33.UW ?U4@: M3//J&E#7A;&R/S]T/\VK!ZOKSZN6 D%=?^")$0T +4BIJNFF9IZEB&B A@RA M&!V;Z%QH92.1)73.UPUU08I8:B^@,JI\5E*%4=5\G"#""XAT1FWX%?# 88T+ M[;>KDKH\NAJQ@!)LKK&_0O[XOM#RW("Y@78/R"P02]V]+P1L&I0DN1*T*BF" MA)"KOF?/&E M57*<++$V;S3YHBY-OP//CKTX:F]R1'R MZ:-F5L\+C0%U?+:IYP69M%V8M%D+^A?4Z;@VF_[&9FFAY%1XHE1T4.ZJ;IQ7 MSY[(7RL4 H7#?8LZ_V94M%W[F@;LRQ;"F0\BC\J3QZ%IA@GJMSR(T@(*!1LP MZ-)B/MRCN:S[TJY!1X>TQK(GM/_O"SX?C9WDV5#@"-%.:[$]+DY].RZFPA(> M*MKF3DK1:#,CE/>^%PIU*\U2/9*MG-(M9!LW8Q)QR2VW\<& ,T&D"-E*H]GJ M_)9%V6)CY'HE_3',H&PZWR3M=_BLT?GQGG.F75Z5Q7D?ES1V9.W>4(EL!(F1Y &0 4Z/Y M_+^L;EPD]P,ZXLZL?L]'S">W;$*ZWHBZE[)LHOCN>XY]N6)Z?K_MW+>O2>^^ M>=_NY;.COQ [O7;K]V[GOM/ND>;M-6G_V?JE>?MSF[3N;FXZO5[G[O99/)K[ MX/$/Z@_!LPX\]Y1<%UM%8NK52FV!KWFG%UL ,XN'30JU$IAG.P&SJ$.U+#8O ME9*:Q@_+@]]22>>#B6W$JOFZ>"%,?;SKWI K?TS=Q P->< T>&(Q6"HG@HX+ MC5POZ-JS0G2"4@[B#D[06:V@'-'LZGQ50KX:;^ Y 'CVHNQ@CKKMVWO2;7^^ MZ]Z_OO'Y' H_I&Y H] 4(#P4P(SRL03Q*@>VR>OSZ4W(,&0D2AJX= ^#EQ( MTPH(%!NU:W8U*_UEZ1CNZY$2%QV@!@KH-!$;0?&C3V0S 0WX.@.U5R:^BE!.LO6XK4G%L6 T]=E8T\$Y#B^AP$Y,,T!88]0DPA9S):@ M^&;8]F#8S,I!H:^BZBY[X#[F>()=4@TI9!N%1E-EW,@'[@7,&KJ>XST 6$Y) MQ[6*>\6XO@_)'+>G%(P4CEM!/98$H3[IC9F%09M-N$LZ@4]:0PB\F'A#^G9( M?X9T"8 WOQ]2VX_NHIVBDENGRQ'B DRZ"2 MA:'K/T22J^L1EW4]CDB!+R%_VMDPMUSY 3,2Z0+0@X!;U(F$J@:Z6"EJ;6[7 M.F9QJ7::S%4I8E'$I6/ZP+2^8/0KIK.YS>KTT0,0;"T=0TY/ID>2P@O) *8N MH4(6!@#3#G8H[9@OJN=&,P46Q!.PUDA[U M@-6IYH1N(68PH9O83B"]6/X@X=PZ#E+P_Y+ M0AG38896/JN>UW*%]_>5X3V==J+J9O6B;)YO(=$#F(.+ M%[$&QU+%,="Y@_A"D%\AO/!M+L.@J[XH8>"1,0DGKPJD7?V8O:0]CEO>:,1] MW!-^DD]E'( 7-!M$P?Q$N07?H%X?=[H]TAZ-'6_&A$135DWG UC0)/B!CLGN ML>Q>W-8-5J=IVX+Y?O3K$WB.QC,L3K70 *>(M*@ MXLZY \Z^_8<^>TDTH++ M.W'O3=QGR..LT.@R>^)Y-D%ZB[(XS=]DS? BS=N=^ PN!Y=;XSLS=%YHM)K; M;_5FN/CL@>/C_(>/=W*BYCQ<%!JUBGY6WB#<6(&D^!@RS*;/" M@#]BU \Y3!C^\N3./\TH?URF%C M% !QI032V((8@GXKX+HM-5]??A\A#@/OSI49&"'#,KBE2FE!<@.BDLG@#J"9 M) [UXYQC\2T1@+O-"WYD1'^R'/YC)'J(&7A_$ MI?RV:#="S!-Y(= !0+FSN&S@.< DML-PGZ/3[-=SD72V:^IJ7ZDI8WZ8H:ZG MDE3+R;"%9-E645]A52*I\L/E2I\ZS^3_(7@ \X5!2.A&'K3_[(Q,W_.S4DF?;W863+H5&)!L01EHX9)S:V^N& M )>*68V@NK";AIMHQ\8Y:7WL$K.L%Z'B/*[*BTG>\/L4_/; %%L@;??A!@P9 M6#/G<. UOR?PS@4#I)5DEI&[T<(;%:H99FSDYR#/[!/'$-](S:SH147Q).4$ MOFG#WK3ALV!HR?%,I3P+@PNQN!L,=G#EM]:*\O>D%1LA"A+4K)0(8^AO6@.V MT"1;,X_[)_O5)47S39M>0ILZOA\R\2(Z57G3J:UTJLRTRK&U7YV*:&ZM4WN. M_E>=MIU[E"HX8@+"JW'N$3,T"7'$!.//#Y#>]O:_Z[W]'3;SMDAGY QQA;J\ MZE[5/;XI1NX&I$VM(6DYU/=?9LMJ5Q&^MKP$1?64&V:]V0BJ_6W$=8CDICQ6 M%J,K7DU>?8/VSB5_##EPU$W6@>SZ](T>'LJ-WJ/W)0VS+_7Y&1L.U4(#G37/ M);W L[X^V6\ZS%9VWL C;52*^(Q1GQ4:S>M_W7P;H\TZ6 1=7(U/-?528WW3 M:[2@ST_2],UVQ_TW$XVY0V]YB7Z*S>)!]\D* MC?9JD?_X[L*H0>2T?A,];ORS;-M230\7T9VOB>@.*J3.8 TZ<7MS)=3YTE[, M$(#,'(@S ,BN)Z..T&>R%L@KVO'!CPUPN9FCWE5%^M[M:Z^[3 MI^;G7KL>7WS+^2W#6)G@(O(2X+./;\9" FEK"1/%$4.R'D%Z# A%\D3TGUG.W#-M^#M>)N\G46 MN?C0V%7 F2!5F(-D78V^01&_U04-GKQ-+_?GXX.WT ^X,PSZ N.??(Q!R6&U ME=PY8?2F5;%65;]CK4J^-..C*C61/8=)9*%EG_X(%GB8777( CZ0G_1,HZ?3)I@,A '1PH#QD> M) J _^#!G6XH[/759&:BX8QD\D> L ME>11)1)0F\^[;HR2(]QEW\&)D)96V6[$ETPQD1[RE:@O0B!1@JUQE#$(.962 M+O8..OETQ:"*)#NY\9ON61.C;)Y\DC>\M$T#C:1"'N6+7@^*TA'Q3?RBWF;V MHF(\ T[E\F.8==T@M#@JDC;%O"@8 XZG4K.C,-0H,D)O)Z00X+&HBZ2I>L\6 MG^*+\S &0R?^$%B5G7/<%U:SX86!#%MQWC- G7#'08.%T08Z>[ 2PC($5?J1 M\8(QXZGCB)8DCK331$ZE-*$+&4);R<**;(ZI0(,0,@R\5?,B0?9LG"+-R$0QWY(2Y'F1 P+$PB8JEG! FL.\P/G<2, MK$)5-/*8C$7](0AV)H$,S#J'KX0X4X0 -')5>V8KY5@IF BEH!,L;6<":63,K8W,FN3G?O#0\L9]:"YR[ M2*!B1 C!1/"0]T$%RD4C\CGC>_,4)VBLQ(#(DXO0RFATXSJ+7G7D+6B_J0OH M+(E-WP+3UPQ,:T7=*'ZOD>G')(,LS8R*45- ?HWLSK%]LM#]:NR:!SZ%LQ]L M*\S5SO)/X1P=J7,X\I==BGYOR8"CO[PH/* MOCS'._I_18"A5PXX]2T/GI+/,#R8*)@#JJ;GF@:4R(\['#,(!&TT#^BQ1\%C M1WXNGN#WXL'A5E_4P\W[>'*.DL7R*+U)"!;Y_W"?\%4_E=#K_'S;O/^]VSYX MM)G^@*7*R/T5ZS(74&& \@(7G06U60E 4+,8,B"2>?1;S!4"4YZU\F-4/P_X>WB?8<+3IB>M= MR2^13S24&2W#,Q+FAT;<59:W/:R!+] M3A7_H8O<;"5;F(?C.+F84(61;+2%P05*C7G=H]ZU>M=)U'7=D]^S_';QKM+M-\X3#S7P> MNJ<3ZQN-.*U8G MD#_/I5(R-$-+&:F#5/S%.^WM\Y*%(MAT7!'R%,9\#5,9,CRI/W+.QY]J"8&L M];JG/?O:%W.A !6&;O.TUVU>DL9W 6@?OB "3YM$0QC84]W*']3[!>TBXE5!J&;4%_;,'4GKF(SH(]J,YX,)E>3J9]UYF,?Q%. MLICUQ9Y^OH!39^+:@^$8G?/LOKGB2 MA7 JI.*>'\E K@1/$5+D->K P)-)+!.FA(Q )BL6H> %L&@!_%JD2D0KR/#L M1 _--W E$I5QD$M0/H=S'O&$!3 H21FQ=3$]4TS1VFK%X@%;LX37P><)1SD> M3Y18(A1$-ZENM_/:J??3AI/NY-Y!AS*)-M_FY1V,?3]XV'E#QYW"/.L[LP61L[2FY M,*3 4@1$;\Z5Q%PD(N+2,./EJU"[LHODMLGU@[50/FC59]Q+N&+)AM84Q.]X M 11. &N6PA]9L#&8VA_J<-AJ'>>.I@H>C#'[5RQ@D8>#=_NP,2]Y\BYN1)UP M3X.FXU!9].L"+CP%+4KH9ZLL53G<-L%MMS!ZHFH%@2)J$S$)3VGS8A^*N&U" MOA,R+POP\,,-0 *'7X51)O7FEX&+(5RM/ _P!4L\W^!]K^&^TYC&\HJ'G:N5?IR(('<$ _Q(HRH34!YGT9:%ER7AV3YSP38['GT, M;U!F#JX.>PGM@:SPJ[.<.W2FY21WR1*V2ECL0Y^P]K%7&(QLP*;OMAT)]_$) M9O5$3Z3VNBL0GG.%2K"08C*BH0*8V0!S*()#K M]$K3[99GUP:XF,^KE<%NL6.9\K$B_&6PBS3%FJ_6$KR I:D)MU1) M[SO-SK&D\!0[9U*U3DK'E'BO>+"I&T)R+\+^QZ'*&.(9,]K=;3H]35N>P]%D MY:67"5]RS.*+W=6-?#G5,B45EJPHHYRA0?GHW*:GN!4Q=ZM5K>"XZR>3*CH M+$"X6+L]_EA&4;>$XPJR:$[-F*4+]B>PQ M,7-O+U$WZK-09@@@D9D^/2N_;T7WE% M^%SW=<:H@3NV9S/X.K2G]N2,/#EOLAY\/V&6^.B('LM2W?*]DLKD>GM& MNV6S6AZG)$5SLOOBE'S([9]BZJ'#E.SS1_Y@W-J=]O(?UHW+';Y&"INNM9WY MDNMBM-TZ9[%P5\#'#\4X_C4M'57H4(H/++!8WCOL2HH%/%&'/7#(#!IS0K8= M4V#I5[(/O>5CAK:SOG01<6/=Q4OC6\1'-;NE?YS#)"STSO= M=,K@]J<+-[U_Q:-319N&YE@<>+(=NH94!JC,JY;^/#%W--,FEH@LH= ^$ZF' MC8J.J%]BR3&6V6?:[OE7,GXD<=F'8!TJ=9NZ6Z/'//K]Z^Z!X_/!QXO6\7GW MI-.JUXX'O<%%M]7];?=E\_!X3U_![3WSG!V?7G5^9ZX-N M@UT/?K_HOF^$,A*[8R%OQ^KH,DXF/&RT6+T&X]LB4B)I'7=Z-_;EN0S4^.AM M\[6,&HR'\C:""<1(-6B93_:U"4]N9;2KXNG1_E2]8^9Z&"L53_2M41RIW53^ M5QP=%-:>MX[Q-27+6!@\._< <^L82VT.]>#TX&W4Z^_O/3[ZS>[O8'O;->&W; MKL[JM=YE^ZK_Z:I_,NA=76YG2U=G]XGBF18^Z=QT^Y\_LM/>U:#;/K\$+?_0 MZUY[#)C2_&KU4.).["+8#M^NUGWXX>/7SN^//K?S^FHF.]SZW\.6W[UYX M;"P2,5PP7R1*CF#/C*= :QC&\_2(K5>J-\_!1A#N6:]_/3A"(;(!T!KQB=!T MR[3$1+@T3*_7*KF^8>_/HP.P^>MN^^JR4^P^!@\F(Q" X:YO!">CDCY4D#=' M*<@0=&0NU5B+7?B)4#Q9X #2@7IMK4; %/_*PL5/T3"=OCOXV6.'^_MO'!4C MOFJ%.9GQD$<^W*SDHU:4;7!S<-[KY\P$_O1%BG0&]5J[S,Y>B9UC8-U0B(@% MP #&@W@*8X#EC/OP6@"DBH*ITR2>R12&I<15X>,4FFN'KUY;B[O/H)KE#;*- M^XLCV%:B7TW)!4AP;;=)?AG$\"&*%1ME":R>,) 5W"8;+^]W66U05F_>I7J M\2^)W=0F'?30ZM$3J'@4 YUV@CAA:3:=AF*"[C?P:$;

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end XML 19 d814195d8k_htm.xml IDEA: XBRL DOCUMENT 0001501756 2024-03-20 2024-03-20 NASDAQ false 0001501756 --12-31 8-K 2024-03-20 Adverum Biotechnologies, Inc. DE 001-36579 20-5258327 100 Cardinal Way Redwood City CA 94063 (650) 656-9323 false false false false Common Stock ADVM false